Modus Therapeutics comments on the start of the first clinical study in the planned sepsis program
Stockholm, Thursday, December 2, 2021. Modus Therapeutics Holding AB ("Modus") announces that the company is set to participate in a live broadcast today at 14:00.Modus' CEO John Öhd will participate in a live broadcast via Infront Direkt Studios today December 2 at 14:00, to comment on the start of the company's clinical Phase 1b LPS provocation study as communicated in yesterday's published press release. To follow the live broadcast, click here For more information on Modus Therapeutics, please contact: John Öhd, VD, Modus Therapeutics Telefon: